Prolactinoma is a growth. It forms in the gland controlling hormones. The pituitary makes many vital substances. These tumors impact cells producing prolactin. That hormone is key for milk production. While not cancerous, prolactinomas cause too much prolactin. This imbalance triggers issues.
Epidemiology
Pituitary tumors happen often. Prolactinomas are 40-60% of them. More women get these growths. For females, the peak years are 20-34. But males tend to get diagnosed later in life. While prolactinomas can develop at any age, women notice them more often during childbearing years. Even so, they remain relatively uncommon. Around 0.3 to 0.5 new cases arise yearly per 100,000 people. Rates may differ across global regions too.
Anatomy
Pathophysiology
These growths develop in the pituitary. They produce excessive prolactin, ignoring dopamine control. Normal prolactin relies on dopamineregulation. But tumor cells disregard this signal, causing a spike. In women, high prolactin disrupts menstrual cycles and fertility. Men face low libido and erectile dysfunction. The tumor mass may compress nearby brain areas too, causing headaches and vision issues. Precise causes remain unclear, but genetics, hormonal changes, medications potentially contribute. Treatment aims to restore dopamine-like effects, lowering prolactin and resolving symptoms. In severe cases, surgery or radiation target tumor removal.
Etiology
Prolactinomas happen when the body malfunctions. Conditions such as MEN1 raise risk. Usually, dopamine stops too much prolactin release. But tumors make cells overproduce prolactin. Pregnancy boosts estrogen, fueling prolactinoma growth. Issues arise during pregnancy, breastfeeding due to increased prolactin needs. Head injuries trigger prolactinomas too. Certain antipsychotic meds, dopamine-affecting drugs contribute. Hypothyroidism also increases risk, though hormonal interactions aren’t fully known.
Genetics
Prognostic Factors
Prolactinomas often have good outcomes if caught early, treated right. Key prognostic factors: tumor size, age at diagnosis, symptoms, treatment response.
Clinical History
Prolactinomas impact males and females uniquely. Females can experience irregular periods, issues conceiving babies, and unintended breast milk production. However, males often struggle with decreased sexual desire and erectile difficulties. Sizeable tumors can squeeze surrounding brain areas like vision nerves, causing severe headaches and sight problems. Long-term, untreated high prolactin levels may weaken bones over time, potentially leading to brittle bone disease. Many patients endure symptoms for extended durations prior to seeking medical attention, exacerbating hormonal imbalances and resulting issues.
Physical Examination
Visible prolactinoma impacts can manifest physically, such as unexpected breast milk production (galactorrhea) in women or enlarged breast tissue (gynecomastia) in men. Loss of vision from compressed optic nerves remains possible. Erectile dysfunction in males, irregular/absent menstruation in females indicate low sex hormone levels. Intense headaches could signal increased intracranial pressure from tumor mass effect.
Age group
Associated comorbidity
Associated activity
Acuity of presentation
Differential Diagnoses
Pituitary tumors
Hypothyroidism
Renal Failure
Laboratory Studies
Imaging Studies
Procedures
Histologic Findings
Staging
Treatment Paradigm
Medicines, termed dopamine agonists, like cabergoline or bromocriptine, serve as primary therapy. Their role: Suppressing prolactin production, hindering tumor expansion. Cabergoline gets preference owing to greater potency. Objectives include: normalizing prolactin levels, restoring fertility ability, relieving symptoms (e.g., breast milk leakage or irregular cycles). Those not seeking fertility can use birth control pills to regulate periods. Regular MRI imaging assesses tumor dimensions. Monitoring prolactin proves crucial. Surgery may become necessary if medications fail or specific issues arise. Approach hinges on tumor size, symptom severity, fertility aspirations, and response to medication.
by Stage
by Modality
Chemotherapy
Radiation Therapy
Surgical Interventions
Surgery may be warranted when medications aren’t tolerated or prove ineffective. Recommendation may also arise if tumor exerts pressure on nearby structures, causing headaches, vision problems, or nerve-related complications. Moreover, certain tumor traits or cyst presence could mandate surgical intervention.
Hormone Therapy
Immunotherapy
Hyperthermia
Photodynamic Therapy
Stem Cell Transplant
Targeted Therapy
Palliative Care
Role of Dopamine Agonist
In contrast to other pituitary tumors, the recommended approach for treating prolactinomas is primarily through medical interventions. If the sole manifestations include amenorrhea or osteoporosis, oral contraceptives alone may be administered.
The preferred pharmacological treatment specifically tailored for prolactinomas involves the use of dopamine agonists.Bromocriptine and cabergoline are widely used dopamine agonists for treating prolactinomas.
Pergolidehas been withdrawn from the market due to concerns about valvular heart disease, and quinagolideis not available in the United States. These dopamine agonists function by suppressing prolactin synthesis and release, as well as inhibiting lactotroph cellular proliferation, resulting in tumor shrinkage.
Bromocriptine, preferred during pregnancy due to more available data than cabergoline, is also cost-effective but has more side effects, such as nausea, nasal stuffiness, vomiting, and postural hypotension. If needed, the dose can be increased every four weeks, up to a maximum of 5 mg twice a day, if prolactin levels are not normalized.
If bromocriptine proves ineffective, cabergoline should be considered as an alternative. The administration of dopamine agonists should be gradually reduced and discontinued if prolactin levels normalize, and there is no detectable tumor on MRI after a minimum of two years of treatment.
Prolactinoma is a growth. It forms in the gland controlling hormones. The pituitary makes many vital substances. These tumors impact cells producing prolactin. That hormone is key for milk production. While not cancerous, prolactinomas cause too much prolactin. This imbalance triggers issues.
Pituitary tumors happen often. Prolactinomas are 40-60% of them. More women get these growths. For females, the peak years are 20-34. But males tend to get diagnosed later in life. While prolactinomas can develop at any age, women notice them more often during childbearing years. Even so, they remain relatively uncommon. Around 0.3 to 0.5 new cases arise yearly per 100,000 people. Rates may differ across global regions too.
These growths develop in the pituitary. They produce excessive prolactin, ignoring dopamine control. Normal prolactin relies on dopamineregulation. But tumor cells disregard this signal, causing a spike. In women, high prolactin disrupts menstrual cycles and fertility. Men face low libido and erectile dysfunction. The tumor mass may compress nearby brain areas too, causing headaches and vision issues. Precise causes remain unclear, but genetics, hormonal changes, medications potentially contribute. Treatment aims to restore dopamine-like effects, lowering prolactin and resolving symptoms. In severe cases, surgery or radiation target tumor removal.
Prolactinomas happen when the body malfunctions. Conditions such as MEN1 raise risk. Usually, dopamine stops too much prolactin release. But tumors make cells overproduce prolactin. Pregnancy boosts estrogen, fueling prolactinoma growth. Issues arise during pregnancy, breastfeeding due to increased prolactin needs. Head injuries trigger prolactinomas too. Certain antipsychotic meds, dopamine-affecting drugs contribute. Hypothyroidism also increases risk, though hormonal interactions aren’t fully known.
Prolactinomas often have good outcomes if caught early, treated right. Key prognostic factors: tumor size, age at diagnosis, symptoms, treatment response.
Prolactinomas impact males and females uniquely. Females can experience irregular periods, issues conceiving babies, and unintended breast milk production. However, males often struggle with decreased sexual desire and erectile difficulties. Sizeable tumors can squeeze surrounding brain areas like vision nerves, causing severe headaches and sight problems. Long-term, untreated high prolactin levels may weaken bones over time, potentially leading to brittle bone disease. Many patients endure symptoms for extended durations prior to seeking medical attention, exacerbating hormonal imbalances and resulting issues.
Visible prolactinoma impacts can manifest physically, such as unexpected breast milk production (galactorrhea) in women or enlarged breast tissue (gynecomastia) in men. Loss of vision from compressed optic nerves remains possible. Erectile dysfunction in males, irregular/absent menstruation in females indicate low sex hormone levels. Intense headaches could signal increased intracranial pressure from tumor mass effect.
Pituitary tumors
Hypothyroidism
Renal Failure
Medicines, termed dopamine agonists, like cabergoline or bromocriptine, serve as primary therapy. Their role: Suppressing prolactin production, hindering tumor expansion. Cabergoline gets preference owing to greater potency. Objectives include: normalizing prolactin levels, restoring fertility ability, relieving symptoms (e.g., breast milk leakage or irregular cycles). Those not seeking fertility can use birth control pills to regulate periods. Regular MRI imaging assesses tumor dimensions. Monitoring prolactin proves crucial. Surgery may become necessary if medications fail or specific issues arise. Approach hinges on tumor size, symptom severity, fertility aspirations, and response to medication.
Surgery may be warranted when medications aren’t tolerated or prove ineffective. Recommendation may also arise if tumor exerts pressure on nearby structures, causing headaches, vision problems, or nerve-related complications. Moreover, certain tumor traits or cyst presence could mandate surgical intervention.
In contrast to other pituitary tumors, the recommended approach for treating prolactinomas is primarily through medical interventions. If the sole manifestations include amenorrhea or osteoporosis, oral contraceptives alone may be administered.
The preferred pharmacological treatment specifically tailored for prolactinomas involves the use of dopamine agonists.Bromocriptine and cabergoline are widely used dopamine agonists for treating prolactinomas.
Pergolidehas been withdrawn from the market due to concerns about valvular heart disease, and quinagolideis not available in the United States. These dopamine agonists function by suppressing prolactin synthesis and release, as well as inhibiting lactotroph cellular proliferation, resulting in tumor shrinkage.
Bromocriptine, preferred during pregnancy due to more available data than cabergoline, is also cost-effective but has more side effects, such as nausea, nasal stuffiness, vomiting, and postural hypotension. If needed, the dose can be increased every four weeks, up to a maximum of 5 mg twice a day, if prolactin levels are not normalized.
If bromocriptine proves ineffective, cabergoline should be considered as an alternative. The administration of dopamine agonists should be gradually reduced and discontinued if prolactin levels normalize, and there is no detectable tumor on MRI after a minimum of two years of treatment.
medtigo
Prolactinoma
Updated :
July 24, 2024
Prolactinoma is a growth. It forms in the gland controlling hormones. The pituitary makes many vital substances. These tumors impact cells producing prolactin. That hormone is key for milk production. While not cancerous, prolactinomas cause too much prolactin. This imbalance triggers issues.
Pituitary tumors happen often. Prolactinomas are 40-60% of them. More women get these growths. For females, the peak years are 20-34. But males tend to get diagnosed later in life. While prolactinomas can develop at any age, women notice them more often during childbearing years. Even so, they remain relatively uncommon. Around 0.3 to 0.5 new cases arise yearly per 100,000 people. Rates may differ across global regions too.
These growths develop in the pituitary. They produce excessive prolactin, ignoring dopamine control. Normal prolactin relies on dopamineregulation. But tumor cells disregard this signal, causing a spike. In women, high prolactin disrupts menstrual cycles and fertility. Men face low libido and erectile dysfunction. The tumor mass may compress nearby brain areas too, causing headaches and vision issues. Precise causes remain unclear, but genetics, hormonal changes, medications potentially contribute. Treatment aims to restore dopamine-like effects, lowering prolactin and resolving symptoms. In severe cases, surgery or radiation target tumor removal.
Prolactinomas happen when the body malfunctions. Conditions such as MEN1 raise risk. Usually, dopamine stops too much prolactin release. But tumors make cells overproduce prolactin. Pregnancy boosts estrogen, fueling prolactinoma growth. Issues arise during pregnancy, breastfeeding due to increased prolactin needs. Head injuries trigger prolactinomas too. Certain antipsychotic meds, dopamine-affecting drugs contribute. Hypothyroidism also increases risk, though hormonal interactions aren’t fully known.
Prolactinomas often have good outcomes if caught early, treated right. Key prognostic factors: tumor size, age at diagnosis, symptoms, treatment response.
Prolactinomas impact males and females uniquely. Females can experience irregular periods, issues conceiving babies, and unintended breast milk production. However, males often struggle with decreased sexual desire and erectile difficulties. Sizeable tumors can squeeze surrounding brain areas like vision nerves, causing severe headaches and sight problems. Long-term, untreated high prolactin levels may weaken bones over time, potentially leading to brittle bone disease. Many patients endure symptoms for extended durations prior to seeking medical attention, exacerbating hormonal imbalances and resulting issues.
Visible prolactinoma impacts can manifest physically, such as unexpected breast milk production (galactorrhea) in women or enlarged breast tissue (gynecomastia) in men. Loss of vision from compressed optic nerves remains possible. Erectile dysfunction in males, irregular/absent menstruation in females indicate low sex hormone levels. Intense headaches could signal increased intracranial pressure from tumor mass effect.
Pituitary tumors
Hypothyroidism
Renal Failure
Medicines, termed dopamine agonists, like cabergoline or bromocriptine, serve as primary therapy. Their role: Suppressing prolactin production, hindering tumor expansion. Cabergoline gets preference owing to greater potency. Objectives include: normalizing prolactin levels, restoring fertility ability, relieving symptoms (e.g., breast milk leakage or irregular cycles). Those not seeking fertility can use birth control pills to regulate periods. Regular MRI imaging assesses tumor dimensions. Monitoring prolactin proves crucial. Surgery may become necessary if medications fail or specific issues arise. Approach hinges on tumor size, symptom severity, fertility aspirations, and response to medication.
Surgery may be warranted when medications aren’t tolerated or prove ineffective. Recommendation may also arise if tumor exerts pressure on nearby structures, causing headaches, vision problems, or nerve-related complications. Moreover, certain tumor traits or cyst presence could mandate surgical intervention.
In contrast to other pituitary tumors, the recommended approach for treating prolactinomas is primarily through medical interventions. If the sole manifestations include amenorrhea or osteoporosis, oral contraceptives alone may be administered.
The preferred pharmacological treatment specifically tailored for prolactinomas involves the use of dopamine agonists.Bromocriptine and cabergoline are widely used dopamine agonists for treating prolactinomas.
Pergolidehas been withdrawn from the market due to concerns about valvular heart disease, and quinagolideis not available in the United States. These dopamine agonists function by suppressing prolactin synthesis and release, as well as inhibiting lactotroph cellular proliferation, resulting in tumor shrinkage.
Bromocriptine, preferred during pregnancy due to more available data than cabergoline, is also cost-effective but has more side effects, such as nausea, nasal stuffiness, vomiting, and postural hypotension. If needed, the dose can be increased every four weeks, up to a maximum of 5 mg twice a day, if prolactin levels are not normalized.
If bromocriptine proves ineffective, cabergoline should be considered as an alternative. The administration of dopamine agonists should be gradually reduced and discontinued if prolactin levels normalize, and there is no detectable tumor on MRI after a minimum of two years of treatment.
Loading...
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Digital Certificate PDF
On course completion, you will receive a full-sized presentation quality digital certificate.
medtigo Simulation
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
medtigo Points
medtigo points is our unique point redemption system created to award users for interacting on our site. These points can be redeemed for special discounts on the medtigo marketplace as well as towards the membership cost itself.
Community Forum post/reply = 5 points
*Redemption of points can occur only through the medtigo marketplace, courses, or simulation system. Money will not be credited to your bank account. 10 points = $1.
All Your Certificates in One Place
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
